IL-22 and Hcy are promising biomarkers for predicting PPROM, PTB, and adverse pregnancy outcomes. Elevated IL-22 reflects immune modulation, while high Hcy correlates with fetal risk and neonatal complications. These findings support their potential application in early diagnosis and risk stratification.
Shikanova et al. (Mon,) studied this question.